Dr. Ana Limón

Dr. Ana Limon holds a PhD in Molecular Biology and Biochemistry from the University of Barcelona. She was a post-doctoral fellow at The Fels Institute for Cancer Research and Molecular Biology (Temple University, Philadelphia, US) and at Dana Farber Cancer Institute (Harvard Medical School, Boston, US) in the fields of cell cycle regulation and cancer Immunology and AIDS, respectively. She was a Research Associate at the Department of Medical Oncology at Dana Farber Cancer Institute working on the characterization of leukemic stem cells, before moving to industry. She was Senior Medical Scientific Liaison for all Oncology assets at Amgen, before moving to Millennium/Takeda where she held increasing responsibility positions to become Head of Oncology Pipeline, Global Medical Affairs at Takeda. In 2021 she moved to Deciphera Pharmaceuticals, where she was Product Leader, responsible for commercial and pipeline assets. Dr. Limón has more than 15 years’ experience in drug development, managing multifunctional teams, conducting research from preclinical to registration-enabling clinical studies in hematologic and solid tumors, as well as Medical Affairs activities for the launch and support of commercial products. Before joining Oryzon’s SAB, Dr. Limón was Senior Vice President of Clinical Development and Global Medical Affairs at Oryzon.